IHH Healthcare Is Trading Below Mean Valuation; Maintain BUY
IHH Healthcare's 1Q21 results was driven by the COVID 19-related services. However, 2Q21 results could be weaker as Singapore and Malaysia (59% of Group’s EBITDA in 1Q21) could be temporarily affected by the renewed lockdowns.
Maintain our earnings forecasts, BUY call and SOP-based target price of MYR6.30 for IHH Healthcare.
We like IHH Healthcare for its undemanding 12-month forward EV/EBITDA of 15x (5-year mean: 20x) and clear strategies in raising its profitability.
IHH's Earnings Within Expectation
Excluding the exceptional items (totalling positive MYR40m), IHH Healthcare's 1Q21 core net profit of MYR336m (+77% y-o-y, -10% q-o-q) accounted for 30% and 33% of our and street’s full-year estimates. We consider the results to be within our expectation as 2Q21 could be sequentially weaker.
Separately, IHH Healthcare's 12-month trailing ROE of 4.5% (FY20: 3%) is near management’s target of at least 5% by 2024.
1Q21: Strong Y-o-y Growth Across All Key Markets
Key takeaways on IHH Healthcare's 1Q21 results:
On a y-o-y basis, occupancy rates of 54%/43%/62% for Singapore, Malaysia and India remained below pre-COVID-19 level. Meanwhile, Acibadem’s occupancy rate of 75% was higher than pre-COVID 19 level (1Q20: 72%) on the return of the foreign patients (16% of Acibadem’s revenue);
All markets revenue of Singapore, India, Malaysia and Acibadem respectively. Additionally, Singapore unit also received government grant of MYR12m in 1Q21 (3% of Singapore’s EBITDA);
GHK registered EBITDA loss of MYR25m in 1Q21 (vs. MYR37m in 1Q20) on occupancy rate of 56% (1Q20: 55%) and management expects GHK to achieve EBITDA breakeven by end-FY21.
2Q21: Could be Affected by the Renewed Lockdowns
We expect the renewed lockdowns at Singapore and Malaysia to adversely affect IHH Healthcare’s higher earnings from COVID-19 related services (i.e. screening, lab test, vaccination) and improvement at India/GHK.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....